$ADMA Stock Loss: ADMA Biologics May Have Misrepresented its Revenue Sources to Investors - Contact BFA Law About The Pending Securities Fraud Class Action

Bleichmar Fonti & Auld LLP issued a shareholder-solicitation notice regarding a class action lawsuit against ADMA Biologics; no new disclosure from the company itself. The lawsuit alleges securities fraud related to channel stuffing and undisclosed related-party transactions, following a short report claiming revenue was inflated.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.